Advanced Search

    Technical Analysis for FULC - Fulcrum Therapeutics, Inc.

    Grade Last Price % Change Price Change
    F 2.85 0.71% 0.02
    FULC closed up 0.71 percent on Friday, March 31, 2023, on approximately normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical FULC trend table...
    Date Alert Name Type % Chg
    Jack-in-the-Box Bearish Bearish Swing Setup 0.00%
    Narrow Range Bar Range Contraction 0.00%
    Inside Day Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    New 52 Week Closing Low Bearish 0.71%
    Expansion Breakdown Bearish Swing Setup 0.71%
    New 52 Week Low Weakness 0.71%
    Wide Bands Range Expansion 0.71%
    Oversold Stochastic Weakness 0.71%
    Older End-of-Day Signals for FULC ...

       Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

    Alert Time
    Possible Inside Day 1 day ago
    60 Minute Opening Range Breakdown 1 day ago
    60 Minute Opening Range Breakout 1 day ago
    Up 5% 1 day ago
    Up 3% 1 day ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    FULC Chart by TradingView
    Basic chart:

    Profile

    Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that are developing for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive, and disabling muscle wasting disorder that leads to significant physical impairments and disability; and FTX-HbF, a small molecule designed to upregulate fetal hemoglobin in patients with sickle cell disease and b-thalassemia. Fulcrum Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biopharmaceutical Disease Disability Disorders Dystrophy Muscular Dystrophy Hemoglobin Progressive Infancy Sickle Cell Disease Thalassemia Facioscapulohumeral Muscular Dystrophy

    Is FULC a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Mar 10 Fulcrum Therapeutics, Inc. (FULC) Q4 2022 Earnings Call Transcript
    Mar 10 Fulcrum Therapeutics downgraded to neutral at Credit Suisse on sickle cell candidate
    Mar 10 United Airlines To Rally Around 54%? Here Are 10 Other Analyst Forecasts For Friday
    Mar 10 Q4 2022 Fulcrum Therapeutics Inc Earnings Call
    Mar 9 Fulcrum plunges 23% after Q4 update as medical chief departs
    Mar 9 Why JD.com Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Mar 9 Fulcrum Therapeutics, Inc. (FULC) Reports Q4 Loss, Misses Revenue Estimates
    Mar 9 Fulcrum Therapeutics GAAP EPS of -$0.50 misses by $0.01, revenue of $0.7M misses by $1.19M
    Mar 9 Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022
    Mar 7 Investors in Fulcrum Therapeutics (NASDAQ:FULC) have unfortunately lost 61% over the last year
    See more FULC news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 24.75
    52 Week Low 2.76
    Average Volume 1,279,484
    200-Day Moving Average 7.39
    50-Day Moving Average 8.38
    20-Day Moving Average 3.95
    10-Day Moving Average 3.18
    Average True Range 0.53
    RSI 20.63
    ADX 49.68
    +DI 12.46
    -DI 43.57
    Chandelier Exit (Long, 3 ATRs) 5.06
    Chandelier Exit (Short, 3 ATRs) 4.35
    Upper Bollinger Bands 6.12
    Lower Bollinger Band 1.79
    Percent B (%b) 0.25
    BandWidth 109.45
    MACD Line -1.47
    MACD Signal Line -1.63
    MACD Histogram 0.161
    Fundamentals Value
    Market Cap 78.27 Million
    Num Shares 27.5 Million
    EPS -50.40
    Price-to-Earnings (P/E) Ratio -0.06
    Price-to-Sales 62.11
    Price-to-Book 3.09
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 3.15
    Resistance 3 (R3) 3.18 3.10 3.10
    Resistance 2 (R2) 3.10 3.03 3.09 3.08
    Resistance 1 (R1) 2.98 2.98 2.95 2.95 3.07
    Pivot Point 2.90 2.90 2.89 2.89 2.90
    Support 1 (S1) 2.78 2.83 2.75 2.75 2.63
    Support 2 (S2) 2.70 2.78 2.69 2.62
    Support 3 (S3) 2.58 2.70 2.60
    Support 4 (S4) 2.55